Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.66
TRIB's Cash-to-Debt is ranked lower than
70% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. TRIB: 0.66 )
Ranked among companies with meaningful Cash-to-Debt only.
TRIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.11 Max: No Debt
Current: 0.66
0.03
No Debt
Equity-to-Asset 0.44
TRIB's Equity-to-Asset is ranked lower than
74% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TRIB: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
TRIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.73 Max: 0.88
Current: 0.44
0.29
0.88
Debt-to-Equity 0.90
TRIB's Debt-to-Equity is ranked lower than
80% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. TRIB: 0.90 )
Ranked among companies with meaningful Debt-to-Equity only.
TRIB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.23 Max: 0.9
Current: 0.9
0
0.9
Debt-to-EBITDA -1.02
TRIB's Debt-to-EBITDA is ranked lower than
99.99% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. TRIB: -1.02 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TRIB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.05  Med: 0 Max: 2.84
Current: -1.02
-3.05
2.84
Interest Coverage 1.12
TRIB's Interest Coverage is ranked lower than
93% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. TRIB: 1.12 )
Ranked among companies with meaningful Interest Coverage only.
TRIB' s Interest Coverage Range Over the Past 10 Years
Min: 1.12  Med: 122.23 Max: 1315.33
Current: 1.12
1.12
1315.33
Piotroski F-Score: 3
Altman Z-Score: 0.69
WACC vs ROIC
7.09%
3.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 5.35
TRIB's Operating Margin % is ranked higher than
61% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. TRIB: 5.35 )
Ranked among companies with meaningful Operating Margin % only.
TRIB' s Operating Margin % Range Over the Past 10 Years
Min: -56.78  Med: 12.17 Max: 67.5
Current: 5.35
-56.78
67.5
Net Margin % -100.00
TRIB's Net Margin % is ranked lower than
74% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. TRIB: -100.00 )
Ranked among companies with meaningful Net Margin % only.
TRIB' s Net Margin % Range Over the Past 10 Years
Min: -101.02  Med: 13.49 Max: 67.4
Current: -100
-101.02
67.4
ROE % -76.58
TRIB's ROE % is ranked lower than
78% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. TRIB: -76.58 )
Ranked among companies with meaningful ROE % only.
TRIB' s ROE % Range Over the Past 10 Years
Min: -76.72  Med: 9.84 Max: 54.77
Current: -76.58
-76.72
54.77
ROA % -36.54
TRIB's ROA % is ranked lower than
67% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. TRIB: -36.54 )
Ranked among companies with meaningful ROA % only.
TRIB' s ROA % Range Over the Past 10 Years
Min: -45.03  Med: 7.27 Max: 41.2
Current: -36.54
-45.03
41.2
ROC (Joel Greenblatt) % -178.05
TRIB's ROC (Joel Greenblatt) % is ranked lower than
67% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. TRIB: -178.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TRIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -178.05  Med: 28.4 Max: 125.23
Current: -178.05
-178.05
125.23
3-Year Revenue Growth Rate -3.30
TRIB's 3-Year Revenue Growth Rate is ranked lower than
71% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. TRIB: -3.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TRIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -30.9  Med: -0.45 Max: 78.4
Current: -3.3
-30.9
78.4
GuruFocus has detected 4 Warning Signs with Trinity Biotech PLC TRIB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TRIB's 30-Y Financials

Financials (Next Earnings Date: 2018-03-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

TRIB Guru Trades in Q4 2016

Chuck Royce 293,330 sh (-33.20%)
Jim Simons 135,950 sh (-42.75%)
» More
Q1 2017

TRIB Guru Trades in Q1 2017

Jim Simons 164,650 sh (+21.11%)
Chuck Royce 293,330 sh (unchged)
» More
Q2 2017

TRIB Guru Trades in Q2 2017

Jim Simons 230,950 sh (+40.27%)
Chuck Royce 182,142 sh (-37.91%)
» More
Q3 2017

TRIB Guru Trades in Q3 2017

Jim Simons 278,450 sh (+20.57%)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TRIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:XPAR:ALMDT, NZSE:PEB, NAS:VRML, NAS:PMD, XTER:ECX, TSE:7707, XKRX:950140, TSE:9707, OSTO:CRAD B, NAS:ONVO, NAS:CEMI, SGX:P8A, NAS:TTOO, TSE:6678, PHS:DNA, XKRX:086040, OSTO:BOUL, LSE:EKF, LSE:AGL, LSE:MXCT » details
Traded in other countries:TRBA.Germany,
Headquarter Location:Ireland
Trinity Biotech PLC develops, manufactures and markets clinical diagnostic products. Its products are used for detecting autoimmune, sexually transmitted diseases, diabetes and disorders of the liver.

Trinity Biotech PLC is in the business of development, manufacture, and marketing of clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It also provides raw materials to life sciences and research industries globally. It markets products under the brand names Unigold, Mardx, Premier, Immublot, EZ, Capita etc. The company derives the majority of its revenues from Americas segment.

Ratios

vs
industry
vs
history
PB Ratio 1.30
TRIB's PB Ratio is ranked higher than
91% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. TRIB: 1.30 )
Ranked among companies with meaningful PB Ratio only.
TRIB' s PB Ratio Range Over the Past 10 Years
Min: 0.23  Med: 1.39 Max: 3.56
Current: 1.3
0.23
3.56
PS Ratio 1.44
TRIB's PS Ratio is ranked higher than
82% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. TRIB: 1.44 )
Ranked among companies with meaningful PS Ratio only.
TRIB' s PS Ratio Range Over the Past 10 Years
Min: 0.16  Med: 2.57 Max: 7.12
Current: 1.44
0.16
7.12
Price-to-Operating-Cash-Flow 17.06
TRIB's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. TRIB: 17.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TRIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.89  Med: 17.52 Max: 442.86
Current: 17.06
1.89
442.86
EV-to-EBIT -1.68
TRIB's EV-to-EBIT is ranked lower than
99.99% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. TRIB: -1.68 )
Ranked among companies with meaningful EV-to-EBIT only.
TRIB' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.2  Med: 12.7 Max: 64.4
Current: -1.68
-2.2
64.4
EV-to-EBITDA -1.68
TRIB's EV-to-EBITDA is ranked lower than
99.99% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. TRIB: -1.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
TRIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.2  Med: 12.7 Max: 64.4
Current: -1.68
-2.2
64.4
EV-to-Revenue 1.64
TRIB's EV-to-Revenue is ranked higher than
81% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. TRIB: 1.64 )
Ranked among companies with meaningful EV-to-Revenue only.
TRIB' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 2 Max: 7.3
Current: 1.64
0.4
7.3
Current Ratio 5.16
TRIB's Current Ratio is ranked higher than
77% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. TRIB: 5.16 )
Ranked among companies with meaningful Current Ratio only.
TRIB' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 3.36 Max: 9.17
Current: 5.16
1
9.17
Quick Ratio 3.77
TRIB's Quick Ratio is ranked higher than
71% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. TRIB: 3.77 )
Ranked among companies with meaningful Quick Ratio only.
TRIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.63 Max: 7.6
Current: 3.77
0.44
7.6
Days Inventory 219.41
TRIB's Days Inventory is ranked lower than
90% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. TRIB: 219.41 )
Ranked among companies with meaningful Days Inventory only.
TRIB' s Days Inventory Range Over the Past 10 Years
Min: 180.54  Med: 205.83 Max: 233.35
Current: 219.41
180.54
233.35
Days Sales Outstanding 96.68
TRIB's Days Sales Outstanding is ranked lower than
72% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. TRIB: 96.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
TRIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.9  Med: 66.84 Max: 96.68
Current: 96.68
47.9
96.68

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -100.00
TRIB's 3-Year Dividend Growth Rate is ranked lower than
89% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. TRIB: -100.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TRIB' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.1
Current: -100
0
30.1
5-Year Yield-on-Cost % 2.01
TRIB's 5-Year Yield-on-Cost % is ranked higher than
65% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. TRIB: 2.01 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TRIB' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.72  Med: 1.05 Max: 2.33
Current: 2.01
0.72
2.33

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 9.75
TRIB's Price-to-Tangible-Book is ranked lower than
64% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.57 vs. TRIB: 9.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TRIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.4  Med: 2.82 Max: 250
Current: 9.75
0.4
250
Price-to-Intrinsic-Value-Projected-FCF 6.54
TRIB's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
83% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. TRIB: 6.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TRIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.27  Med: 1.45 Max: 7.05
Current: 6.54
0.27
7.05
Price-to-Median-PS-Value 0.56
TRIB's Price-to-Median-PS-Value is ranked higher than
77% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. TRIB: 0.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TRIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 0.73 Max: 2.51
Current: 0.56
0.09
2.51
Earnings Yield (Greenblatt) % -59.56
TRIB's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. TRIB: -59.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TRIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -146.4  Med: 4.9 Max: 84.7
Current: -59.56
-146.4
84.7
Forward Rate of Return (Yacktman) % -11.85
TRIB's Forward Rate of Return (Yacktman) % is ranked lower than
91% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. TRIB: -11.85 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TRIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -32.4  Med: -0.6 Max: 2.5
Current: -11.85
-32.4
2.5

More Statistics

Revenue (TTM) (Mil) $98.27
EPS (TTM) $ -4.32
Beta1.28
Short Percentage of Float0.00%
52-Week Range $4.22 - 7.05
Shares Outstanding (Mil)24.04 (ADR)

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.29
EPS without NRI ($) 0.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}